Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44+/Musashi-1+ gastric cancer stem cells

Cancer Letters

Volumn 369, Issue 1, 2015, Pages 124-133

  Xu, Min ^a   Gong, Aihua ^b   Yang, Hongqiong ^a   George, Suraj K ^c   Jiao, Zhijun ^a   Huang, Hongmei ^a   Jiang, Xiaomeng ^a   Zhang, Youli ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ABCG2; Chemoresistance; Gastric cancer xenograft; SHH GLI

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CELL MARKER; DOXORUBICIN; GANT 61; HERMES ANTIGEN; MUSASHI 1; RNA BINDING PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANILIDE; ANTINEOPLASTIC ANTIBIOTIC; CD44 PROTEIN, HUMAN; GLI1 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; SHH PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL CLONE; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; GLIOMA ASSOCIATED ONCOGENE HOMOLOG 1; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; CELL SELF-RENEWAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HEK293 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANILIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD44; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL SELF RENEWAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HEDGEHOG PROTEINS; HEK293 CELLS; HUMANS; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PYRIDINES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943450263     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.08.005     Document Type: Article

References (50)

1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., et al. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013, International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr.
2. Yang D., Hendifar A., Lenz C., Togawa K., Lenz F., Lurje G., et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J. Gastrointest. Oncol 2011, 2:77-84.
3. Wagner A.D., Unverzagt S., Grothe W., Kleber G., Grothey A., Haerting J., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev 2010, (3). CD004064.
4. Abdullah L.N., Chow E.K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med 2013, 2:3.
5. Chow E.K., Fan L.L., Chen X., Bishop J.M. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology 2012, 56:1331-1341.
6. Sastry K.S., Al-Muftah M.A., Li P., Al-Kowari M.K., Wang E., Ismail Chouchane A., et al. Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. Cell Death Differ 2014, 21:1936-1949.
7. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
8. Wang C., Xie J., Guo J., Manning H.C., Gore J.C., Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol. Rep 2012, 28:1301-1308.
9. Takaishi S., Okumura T., Tu S., Wang S.S., Shibata W., Vigneshwaran R., et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020.
10. Li K., Dan Z., Nie Y.Q. Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment. World J. Gastroenterol 2014, 20:5420-5426.
11. Wang T., Ong C.W., Shi J., Srivastava S., Yan B., Cheng C.L., et al. Sequential expression of putative stem cell markers in gastric carcinogenesis. Br. J. Cancer 2011, 105:658-665.
12. Chen S., Hou J.H., Feng X.Y., Zhang X.S., Zhou Z.W., Yun J.P., et al. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J. Surg. Oncol 2013, 107:799-806.
13. Kuang R.G., Kuang Y., Luo Q.F., Zhou C.J., Ji R., Wang J.W. Expression and significance of Musashi-1 in gastric cancer and precancerous lesions. World J. Gastroenterol 2013, 19:6637-6644.
14. Nakano A., Kanemura Y., Mori K., Kodama E., Yamamoto A., Sakamoto H., et al. Expression of the Neural RNA-binding protein Musashi1 in pediatric brain tumors. Pediatr. Neurosurg 2007, 43:279-284.
15. Gotte M., Wolf M., Staebler A., Buchweitz O., Kelsch R., Schuring A.N., et al. Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma. J. Pathol 2008, 215:317-329.
16. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond.) 2012, 7:597-615.
17. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:15665-15670.
18. Singh R.R., Kunkalla K., Qu C., Schlette E., Neelapu S.S., Samaniego F., et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011, 30:4874-4886.
19. Song Z., Yue W., Wei B., Wang N., Li T., Guan L., et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS ONE 2011, 6:e17687.
20. Kalderon D. Transducing the hedgehog signal. Cell 2000, 103:371-374.
21. Ahmad A., Maitah M.Y., Ginnebaugh K.R., Li Y., Bao B., Gadgeel S.M., et al. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J. Hematol. Oncol 2013, 6:77.
22. Chen Y.J., Kuo C.D., Chen S.H., Chen W.J., Huang W.C., Chao K.S., et al. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells. PLoS ONE 2012, 7:e37006.
23. Liu Z., Xu J., He J., Zheng Y., Li H., Lu Y., et al. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 2014, 124:2061-2071.
24. Yoon C., Park do J., Schmidt B., Thomas N.J., Lee H.J., Kim T.S., et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin. Cancer Res 2014, 20:3974-3988.
25. Barrandon Y., Green H. Three clonal types of keratinocyte with different capacities for multiplication. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:2302-2306.
26. Akasaka Y., Saikawa Y., Fujita K., Kubota T., Ishikawa Y., Fujimoto A., et al. Expression of a candidate marker for progenitor cells, Musashi-1, in the proliferative regions of human antrum and its decreased expression in intestinal metaplasia. Histopathology 2005, 47:348-356.
27. Katoh Y., Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med 2009, 9:873-886.
28. Xu M., Li L., Liu Z., Jiao Z., Xu P., Kong X., et al. ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance. Cancer Lett 2013, 333:152-158.
29. Chen Y., Bieber M.M., Teng N.N. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol. Carcinog 2014, 53:625-634.
30. Zahreddine H., Borden K.L. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol 2013, 4:28.
31. Li H., Chen X., Calhoun-Davis T., Claypool K., Tang D.G. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008, 68:1820-1825.
32. Snyder D.A. One medical center's journey into continuous quality improvement. Mil. Med 1992, 157:328-329.
33. Zhou Z.H., Ping Y.F., Yu S.C., Yi L., Yao X.H., Chen J.H., et al. A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett 2009, 281:92-99.
34. Gulmann C., Grace A., Leader M., Butler D., Patchett S., Kay E. CD44v6: a potential marker of malignant transformation in intestinal metaplasia of the stomach? An immunohistochemical study using tissue microarrays. Eur. J. Gastroenterol. Hepatol 2003, 15:981-986.
35. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S.R., Wesselborg S., Schulze-Osthoff K., et al. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med 2008, 14:450-460.
36. Potten C.S., Booth C., Tudor G.L., Booth D., Brady G., Hurley P., et al. Identification of a putative intestinal stem cell and early lineage marker; musashi-1. Differentiation 2003, 71:28-41.
37. Gotte M., Greve B., Kelsch R., Muller-Uthoff H., Weiss K., Kharabi Masouleh B., et al. The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1. Int. J. Cancer 2011, 129:2042-2049.
38. Katsuno Y., Ehata S., Yashiro M., Yanagihara K., Hirakawa K., Miyazono K. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J. Pathol 2012, 228:391-404.
39. Liu J., Ma L., Xu J., Liu C., Zhang J., Liu J., et al. Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int. J. Oncol 2013, 42:453-459.
40. Wakamatsu Y., Sakamoto N., Oo H.Z., Naito Y., Uraoka N., Anami K., et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol. Int 2012, 62:112-119.
41. Kim J., Lee J.J., Kim J., Gardner D., Beachy P.A. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13432-13437.
42. Lauth M., Bergstrom A., Shimokawa T., Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:8455-8460.
43. Sandhiya S., Melvin G., Kumar S.S., Dkhar S.A. The dawn of hedgehog inhibitors: vismodegib. J. Pharmacol. Pharmacother 2013, 4:4-7.
44. Dijkgraaf G.J., Alicke B., Weinmann L., Januario T., West K., Modrusan Z., et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011, 71:435-444.
45. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug. Discov 2006, 5:219-234.
46. Lou H., Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007, 26:1357-1360.
47. Santisteban M. ABC transporters as molecular effectors of pancreatic oncogenic pathways: the Hedgehog-GLI model. J. Gastrointest. Cancer 2010, 41:153-158.
48. Vasiliou V., Vasiliou K., Nebert D.W. Human ATP-binding cassette (ABC) transporter family. Hum. Genomics 2009, 3:281-290.
49. Zahreddine H.A., Culjkovic-Kraljacic B., Assouline S., Gendron P., Romeo A.A., Morris S.J., et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature 2014, 511:90-93.
50. Zeng X., Zhao H., Li Y., Fan J., Sun Y., Wang S., et al. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Autophagy 2015, 11:355-372.